Given the major hematological alterations observed in humans with JAK372 deficiency (underlying SCID) and JAK2KO mice, we hypothesized that impaired JAK2 expression in MCTS1-deficient patients would lead to abnormal myeloid or lymphoid development. Here, JAK2 is linked to severe combined immunodeficiency.